The need for new coronavirus disease 2019 (COVID-19) therapeutic strategies continues, especially as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants emerge. Zhang and colleagues elegantly engineered a mutant angiotensin-converting enzyme 2 (ACE2) that competitively binds SARS-CoV-2 spike protein, reduces viral uptake by human lung cells, and ameliorates SARS-CoV-2-induced lung injury in mice expressing human ACE2.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882396 | PMC |
| http://dx.doi.org/10.1016/j.tips.2022.02.010 | DOI Listing |
Publication Analysis
Top Keywords
decoy mutant
4
mutant ace2
4
ace2 designed
4
designed reduce
4
reduce covid-19
4
covid-19 coronavirus
4
coronavirus disease
4
disease 2019
4
2019 covid-19
4
covid-19 therapeutic
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!